Clinical Trials Logo

Clinical Trial Summary

A Double blinded (oral), Open Label, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in healthy Subjects to establish the safety, tolerability, bioavailability, pharmacokinetic, and pharmacodynamic profile and the of Entera's oral PTH(1 - 34) in adult healthy human volunteers.


Clinical Trial Description

This study will have three stages. Stage 1: Safety and initial bioavailability of Entera's oral EP101 in adult male healthy volunteers. (SA-BA) Stage 2: Assessment of bioavailability and safety of Entera's oral EP101 in adult male healthy volunteers. (SA-BA-PK-PD) Stage 3: Safety, PK, and PD of final dose of Entera's oral PTH(1 - 34) in adult healthy male and female volunteers. (SA-BA-PK-PD) ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02202603
Study type Interventional
Source Entera Bio Ltd.
Contact
Status Completed
Phase Phase 1
Start date July 2011
Completion date August 2013

See also
  Status Clinical Trial Phase
Completed NCT01425502 - Data-driven Quality Improvement in Primary Care - Trial N/A
Recruiting NCT01756183 - Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer Phase 2
Completed NCT01355016 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers Phase 1
Completed NCT01757860 - Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects Phase 1
Completed NCT01179854 - Remegal Different Doses in Patients With Refractory Partial Seizures Phase 2
Completed NCT00376415 - A Safety Study of Lessertia Frutescens in Adults. Phase 1
Active, not recruiting NCT01722916 - Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase Early Phase 1
Completed NCT01727778 - Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01475097 - Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography Phase 4
Completed NCT01412658 - Clinical Safety of a Novel Milk Protein Peptide Phase 1
Terminated NCT01847222 - An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATEā„¢ in Healthy Volunteers. Phase 1
Unknown status NCT01633099 - Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Phase 3
Recruiting NCT01297842 - Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections Phase 4
Completed NCT01284582 - Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) Phase 1
Completed NCT01557270 - Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery Phase 3
Completed NCT01556607 - A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma Phase 1
Completed NCT01319903 - Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 Phase 1
Completed NCT01271569 - A Study to Assess the Efficacy and Safety of Fospropofol Disodium Phase 1
Recruiting NCT04785027 - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis Phase 1/Phase 2
Completed NCT01367873 - Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects Phase 1